Outcomes at 2-Years Follow-Up After Hip Arthroscopy Combining Bone Marrow Concentrate. Issue 7 (8th August 2020)

• Record Type: Journal Article
• Authors: Rivera, Eila; Seijas, Roberto; Rubio, Mónica; García-Balletbó, Montserrat; Vilar, Jose Manuel; Boada, Patricia Laiz; Cugat, Ramón
• Is Part Of: Journal of investigative surgery. Volume 33:Issue 7(2020)
• Page Start: 655
• Page End: 663
• Publication Date: 2020-08-08
• Subjects: hip arthroscopy -- marrow concentrate -- cartilage -- osteoarthritis -- femoroacetabular impingement -- bone marrow concentrate; Surgery -- Research -- Periodicals; Research; Surgery; Surgical Procedures, Operative; 617.075
• DOI: 10.1080/08941939.2018.1535010
• Languages: English
• ISSNs: 0894-1939

Abstract

Abstract: Introduction: The cartilage injuries are related to femoroacetabular impingement (FAI). The prognostic of the injury depends on the grade of itself. Using bone marrow concentrate (BMC), which contains stem cells, is related to the improvement in diverse tissues. The purpose of this study was to evaluate the improvement of the patients after a FAI arthroscopic intervention using BMC. We compared the results to those of a previous cohort of patients who had identical surgery but without BMC. Methods: A cohort study was conducted between 2015 and 2017. Forty patients with FAI that underwent hip arthroscopy surgery combined with BMC were included. A control group of 40 patients with identical characteristics operated without BMC therapy. VAS, mHHS, and iHOT-33 preoperatively and at 3, 6, 12, and 24 months data were obtained and analyzed. Results: Significant differences between two groups where found at 12 and 24 months of follow-up. VAS values were significantly lower ( p = 0.007 and p = 0.000). Pain and functional scales mHHS ( p = 0.004 and p = 0.001) and iHOT ( p = 0.033 and p = 0.024) were significantly higher in the study group. Conclusions: The use of BMC as coadyuvant in arthroscopic intervention of FAI injuries results in pain reduction and improvement in functionality as showed in VAS, mHHS, and iHOT-33 scores at 12 and 24 months of follow-up. Level of Evidence : Level of Evidence III, Case control study